NASDAQ true 0001711279 0001711279 2021-03-24 2021-03-24





Washington, D.C. 20549




(Amendment No. 1)




Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 24, 2021




(Exact name of registrant as specified in its charter)




Delaware   001-38210   82-1080209

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification Number)

2100 Wharton Street, Suite 701

Pittsburgh, Pennsylvania 15203

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (412) 586-5830



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock   KRYS   Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





On March 24, 2021, Krystal Biotech, Inc. (the “Company”) filed a Current Report on Form 8-K reporting that it had issued a press release announcing the launch of Jeune, Inc. (which has subsequently been renamed Jeune Aesthetics, Inc) (“Jeune”), a gene-based aesthetics company, and the initial safety data from the ongoing Phase 1 trial of KB301 for aesthetic indications. Jeune continues to manage the development of a portfolio of aesthetic indication candidates based on the Company’s proprietary technology platform. The formal license between the Company and Jeune referred to in the press release has not been finalized as Jeune remains a wholly-owned subsidiary of the Company. The Company furnished the press release on a Current Report on Form 8-K dated March 24, 2021 under Item 7.01. The Company is filing this amendment to such Current Report solely to correct the disclosure within the press release attached to such Current Report and incorporated therein.


Item 7.01

Regulation FD Disclosure.

The information under “Explanatory Note” above is incorporated into this Item 7.01 by reference.

This information in this Item 7.01 of this Current Report on Form 8-K/A shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing.


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 19, 2021     KRYSTAL BIOTECH, INC.

/s/ Krish S. Krishnan

    Name:   Krish S. Krishnan
    Title:   Chairman and Chief Executive Officer